Curasight presents at HC Andersen Capital
Curasight A/S (“Curasight” or the “Company”) CEO Ulrich Krasilnikoff and CSO professor Andreas Kjær will present the Interim Report Q3 2021 at HC Andersen Capital, 25 November 2021.
The presentation will be webcasted live 12:00 - 12:30 (CET), Thursday 25 November 2021.
For more information – please click here
For more information regarding Curasight, please contact:
Ulrich Krasilnikoff, CEO
Phone: +45 22 83 01 60
Curasight is a clinical development company based in Copenhagen, Denmark. The company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology is expected to improve diagnosis and risk stratification in multiple cancer types.